CGNH (CGNH) Stock Price & Analysis
CGNH (CGNH) rose 0.00% to USD 0 as of June 10, 2026 at 11:10 UTC, according to Nexqual real-time market data.
CGNH last closed at USD 0; the session ranged USD 0–0 on volume of 3,066 shares. Market capitalization is $9,605, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 11:10 UTC.
Key Statistics (as of June 10, 2026 at 11:10 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 3,066 shares |
| Market Cap | $9,605 |
| Exchange | PNK |
Technical Analysis (CGNH)
Nexqual's technical model rates CGNH "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 11:10 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (CGNH)
Wall Street analysts rate CGNH "None", per Nexqual as of June 10, 2026 at 11:10 UTC.
| Consensus Rating | None |
|---|
Earnings (CGNH)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2011-10-31 | USD -0.01 vs est -0.01 ▲ beat |
| 2011-07-31 | USD -0.01 vs est -0.01 ▲ beat |
| 2011-04-30 | USD -0.01 vs est -0.01 ▲ beat |
| 2011-01-31 | USD 0 vs est -0.01 ▲ beat |
Source: Nexqual, June 10, 2026 at 11:10 UTC.
Financials & Fundamentals (CGNH)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.16 |
| Total Cash | $96,810 |
| Total Debt | $378,496 |
| Free Cash Flow | $-663,818 |
Source: Nexqual, June 10, 2026 at 11:10 UTC.
Financial Health Score (CGNH)
Nexqual rates CGNH's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 11:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $97K cash, no debt |
| Cash Flow | Weak — FCF negative: -$664K, burning cash |
| Efficiency | Mixed — No data |
Ownership (CGNH)
| Insider Ownership | +2.52% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 96.05M |
| Float | 99.88M |
Source: Nexqual, June 10, 2026 at 11:10 UTC.
Leadership (CGNH)
CGNH is led by Yahia Abdul Gawad Ch.B., M.D., MB, MSc. (age 67), Founder, CEO & Director, per Nexqual as of June 10, 2026 at 11:10 UTC.
| Founder, CEO & Director | Yahia Abdul Gawad Ch.B., M.D., MB, MSc. (age 67) |
|---|---|
| Chief Financial Officer | James A. Essex CA (age 76) |
| Corporate Secretary & Director | Linda J. Sterling F.Inst.L.C.O. (age 64) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BZYR | Burzynski Research Institute, I | USD 0.01 | ▲ 0% |
| PFND | PATHFINDER CELL THERAPY INC | USD 0 | ▲ 0% |
| FPMI | FLUOROPHARMA MEDICAL INC | USD 0 | ▲ 0% |
| ARNI | ARNO THERAPEUTICS INC | USD 0 | ▲ 0% |
| MRPI | MERA PHARMACEUTICALS INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 11:10 UTC. This page is informational and not investment advice.